Biofil Chemicals Pharmaceuticals Ltd vs Gujarat Terce Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Biofil Chemicals & Pharmaceuticals Ltd is ₹ 34.44 as of 06 May 15:30 . The P/E Ratio of Biofil Chemicals & Pharmaceuticals Ltd changed from 86.4 on March 2021 to 121 on March 2025 . This represents a CAGR of 6.97% over 5 yearsThe P/E Ratio of Gujarat Terce Laboratories Ltd changed from 22.2 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 106.81 crore on March 2021 to ₹ 66.92 crore on March 2025 . This represents a CAGR of -8.93% over 5 yearsThe Market Cap of Gujarat Terce Laboratories Ltd changed from ₹ 5.16 crore on March 2021 to ₹ 45.37 crore on March 2025 . This represents a CAGR of 54.46% over 5 years The revenue of Biofil Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.93 crore as compare to the Sep '25 revenue of ₹ 13.6 crore. This represent the decline of -93.16% The revenue of Gujarat Terce Laboratories Ltd for the Dec '25 is ₹ 12.42 crore as compare to the Sep '25 revenue of ₹ 12.98 crore. This represent the decline of -4.31% The ebitda of Biofil Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.17 crore as compare to the Sep '25 ebitda of ₹ 0.18 crore. This represent the decline of -5.56% The ebitda of Gujarat Terce Laboratories Ltd for the Dec '25 is ₹ 1.26 crore as compare to the Sep '25 ebitda of ₹ 1.94 crore. This represent the decline of -35.05% The net profit of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 0.17 crore to ₹ 0.08 crore over 7 quarters. This represents a CAGR of -35.00% The net profit of Gujarat Terce Laboratories Ltd changed from ₹ -0.08 crore to ₹ 0.76 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Biofil Chemicals & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Gujarat Terce Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals Limited (BCPL) was incorporated as a Private Limited Company on 4 Jan.'85 for manufacturing and trading of Pharmaceuticals products.
Later on, the Company was converted into a Public Limited Company on 7 May '92.
The Company deals in providing job work facility in respect of manufacturing of pharmaceuticals drug.
It runs the business via two unit viz Pharmaceutical Division & Chemicals Division. In Feb.'96, the company had come out with a rights-cum-public issue at a premium of Rs 7.50 and at a premium of Rs 12.50 respectively, both aggregating Rs 23.21 cr, to part-finance its expansion and diversification into bulk drugs and pharmaceutical formulations.
The company currently manufactures pharmaceutical formulations like injections, capsules, eye-drops and dry syrups at its plant located in Indore.

About Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Limited, incorporated in 1985, is a trusted manufacturer of high quality medication at affordable rates for the common man.
Company specialise in producing oral solid dosages, including tablets and capsules, that address various therapeutic needs. Headquartered in Ahmedabad, Gujarat, Terce offers an extensive portfolio featuring over 125 products and more than 64 well-established brands. By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing.
In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange.
In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat.
As India heralded new leaps in the pharma sector to become a global force to reckon with by 2005, the Company closely followed the narrative with ferocious growth expanding presence in the domestic and international market.

FAQs for the comparison of Biofil Chemicals & Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd

Which company has a larger market capitalization, Biofil Chemicals & Pharmaceuticals Ltd or Gujarat Terce Laboratories Ltd?

Market cap of Biofil Chemicals & Pharmaceuticals Ltd is 56 Cr while Market cap of Gujarat Terce Laboratories Ltd is 28 Cr

What are the key factors driving the stock performance of Biofil Chemicals & Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd?

The stock performance of Biofil Chemicals & Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biofil Chemicals & Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd?

As of May 6, 2026, the Biofil Chemicals & Pharmaceuticals Ltd stock price is INR ₹34.44. On the other hand, Gujarat Terce Laboratories Ltd stock price is INR ₹36.64.

How do dividend payouts of Biofil Chemicals & Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd compare?

To compare the dividend payouts of Biofil Chemicals & Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.